Spanish Red Biotech Pipeline

Minoryx

MIN-102 (leriglitazone)

Type: Biodrugs/ Drugs
Therapeutic area:
Indication: Acute X-linked Adrenoleukodystrophy (cALD; cerebral ALD)
Phase: 3Phase III, 2Phase II, 1Phase I, 2Regulatory Preclinical, 1Non Regulatory Preclinical